Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer

Abstract Background A standard of care for pretreated, advanced non–small‐cell lung cancers (NSCLCs), nivolumab has demonstrated long‐term benefit when administered for 2 years. We aimed to better discern an optimized administration duration by retrospectively analyzing real‐life long‐term efficacy...

Full description

Bibliographic Details
Main Authors: Margaux Geier, Renaud Descourt, Romain Corre, Guillaume Léveiller, Régine Lamy, Éric Goarant, Jean‐Louis Bizec, Cyril Bernier, Gilles Quéré, Karim Amrane, Elisabeth Gaye, François Lucia, Emilie Burte, Christos Chouaid, Gilles Robinet
Format: Article
Language:English
Published: Wiley 2020-10-01
Series:Cancer Medicine
Subjects:
immunotherapy
long‐term survivors
nivolumab
non–small‐cell lung cancer
real‐life
treatment duration
Online Access:https://doi.org/10.1002/cam4.3120

Internet

https://doi.org/10.1002/cam4.3120

Similar Items